Oppenheimer Upgrades Homology Medicines (FIXX) to Outperform
Tweet Send to a Friend
Oppenheimer analyst Matthew Biegler upgraded Homology Medicines (NASDAQ: FIXX) from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


